StockNews.com Begins Coverage on CytRx (NASDAQ:CYTR)

StockNews.com initiated coverage on shares of CytRx (NASDAQ:CYTRGet Rating) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the stock.

CYTR stock opened at $0.15 on Thursday. The firm’s 50 day moving average is $0.30. CytRx has a 12-month low of $0.10 and a 12-month high of $4.70. The firm has a market cap of $6.52 million, a P/E ratio of -1.00 and a beta of 2.18.

CytRx Company Profile (Get Rating)

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.

Featured Articles

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.